Inhibitors of poly (ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated
single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to …

Ovarian cancer is the most lethal gynecologic malignancy, characterized by a high death-to-
incidence ratio. Platinum-based chemotherapy is the mainstay of treatment for newly …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the
ovarian cancer (OC) treatment landscape. This narrative review provides a comprehensive …

Background: Ovarian cancer remains the most common lethal gynecologic malignancy. The
therapeutic gains with the use of traditional cytotoxic chemotherapy in advanced stage …

Background Poly-ADP-ribose polymerase (PARP) inhibitors have emerged as a novel class
of therapeutics for ovarian cancer (OC); however, PARP inhibitors present a class effect …

Background In recurrent ovarian cancer, poly (ADP-ribose) polymerase (PARP)-inhibiting
agents have transformed the treatment of platinum-sensitive disease. New data support use …

Inhibitors of poly (ADP-ribose) polymerase (PARP) are considered one of the most active
and exciting new therapies for the treatment of ovarian cancer. The anticancer activity of …

PURPOSE To provide recommendations on the use of poly (ADP-ribose) polymerase
inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer …

Opinion statement Use of poly (ADP-ribose) polymerase (PARP) inhibitors has greatly
increased over the past 5 years. With several new Food and Drug Administration (FDA) …

In the last year, treatment with PARPi has extended to not only include BRCAm and HRD-
deficient patients but also have shown improvement in outcomes in HRD-proficient patients …